-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Vedolizumab was the first biologic approved for the treatment of inflammatory bowel disease after the era of tumor necrosis factor antagonists (anti-TNF)
Vedolizumab was the first biologic approved for the treatment of inflammatory bowel disease after the era of tumor necrosis factor antagonists (anti-TNF)
The researchers screened patients with CD and UC identified for vedolizumab based on two national health care databases in the United States and France
statistics
Study results showed that among a total of 10,299 vedolizumab users, at week 26, 236 (29.
In this study, we found that vedolizumab and thiopurine combination therapy had lower treatment failure rates in CD compared with vedolizumab monotherapy in two large cohorts, but not in UC.
In this study, we found that vedolizumab and thiopurine combination therapy had lower treatment failure rates in CD compared with vedolizumab monotherapy in two large cohorts, but not in UC.
Original source:
Julien Kirchgesner.
Julien Kirchgesner.
et al.
Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease.
GUT.
2022.
Decresed risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease.
Leave a comment here
